Serum albumin concentration: A predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 5, 2010, Pages 297-308

  Fasanmade, A A ^a   Adedokun, O J ^a   Olson, A ^b   Strauss, R ^a   Davis, H M ^a  

^a CENTOCOR INC   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Albumin; Infliximab; Monoclonal antibody drugs; Neonatal Fc receptor; Ulcerative colitis

Indexed keywords

ALBUMIN; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; CORTICOSTEROID; CREATININE; FC RECEPTOR; IMMUNOGLOBULIN G; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PLACEBO;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; PREDICTION; TREND STUDY; ULCERATIVE COLITIS;

EID: 77952778634     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48297     Document Type: Article

References (29)

1. Anderson CL, Chaudhury C, Kim J, Bronson CL, Wani MA, Mohanty S. Perspective - FcRn transports albumin: relevance to immunology and medicine. Trends Immunol. 2006; 27: 343-348. (Pubitemid 43963476)
2. Baker M, Parton T. Kinetic determinants of hepatic clearance: plasma protein binding and hepatic uptake. Xenobiotica. 2007; 37: 1110-1134. (Pubitemid 350035537)
3. Bergogne-Bérézin E. Clinical role of protein binding of quinolones. Clin Pharmacokinet. 2002; 41: 741-750. (Pubitemid 34948195)
4. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41.
5. Dennis MS, Zhang M, Y Meng YG, Kadkhodayan M, Kirchhofer D, Combs D, Damico LA. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem. 2002; 277: 35035-35043.
6. Fasanmade AA, Olson A, Bao W, Pendley C, Davis H, Mayer L. Relationship between infliximab pharmacokinetics and improvement in Crohn's disease. Gastroenterology. 2002; 122 (Suppl): A617-A618.
7. Fasanmade AA, Marsters P, Munsanje E, Graham MA, Davis HM, Van Deventer S. Infliximab pharmacokinetics and improvement in fistulizing Crohn's disease. Gastroenterology. 2003; 124 (Suppl): A61.
8. Fasanmade AA, Adedokun OJ, Ford J, Hernandez D, Johanns J, Hu C, Davis HM, Zhou H. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol. 2009; 65: 1211-1228.
9. Gottlieb AB, Masud S, Ramamurthi R, Abdulghani A, Romano P. Chaudhari U, Dooley LT, Fasan-made AA, Wagner CL. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol. 2003; 48: 68-75. (Pubitemid 36091536)
10. Gurbaxani B. Mathematical modeling as accounting: Predicting the fate of serum proteins and therapeutic monoclonal antibodies. Clin Immunol. 2007; 122: 121-124. (Pubitemid 46091771)
11. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004; 2: 542-553. (Pubitemid 38834038)
12. Humira [package insert]. Abbott Laboratories, Abbott Park, IL, 2008.
13. Jacobson S, Kallner A. Effect of total parenteral nutrition on serum concentrations of eight proteins in Crohn's disease. Am J Gastroenterol. 1984; 79: 501-505. (Pubitemid 14091504)
14. Kim J, Bronson CL, Hayton WL, Radmacher MD, Roopenian DC, Robinson JM, Anderson CL. Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am J Physiol Gastrointest Liver Physiol. 2006; 290: G352-G360.
15. Kim J, Hayton WL, Robinson JM, Anderson CL. Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin Immunol.2007; 122: 146-155. (Pubitemid 46073892)
16. Klidjian AM, Archer TJ, Foster KJ, Karran SJ. Detection of dangerous malnutrition. J Parenter Enteral Nutr. 1982; 6: 119-121.
17. Maini RN, Breedveld F, Kaldan JR, Smolen JS, Davis D, Macfarlane JD. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor [alpha] monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998; 41: 1552-1563. (Pubitemid 28459913)
18. Nguyen A, Reyes AI, Zhang M, McDonald P, Wong WLT, Damico LA, Dennis MS. The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Protein Eng Des Sel. 2006; 19: 291-297. (Pubitemid 43999639)
19. Remicade [package insert]. Centocor Ortho Biotech, Inc., Malvern, PA, 2009.
20. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007; 7: 715-725. (Pubitemid 47327396)
21. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462-2476. (Pubitemid 41770166)
22. Seidler U, Lenzen H, Cinar A, Tessema T, Bleich A, Riederer B. Molecular mechanisms of disturbed electrolyte transport in intestinal inflammation. Ann N Y Acad Sci. 2006; 1072: 262-275. (Pubitemid 44448459)
23. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med. 1987; 317: 1625-1629.
24. St. Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, Keystone EC. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis. Arthritis Rheum. 2002; 46: 1451-1459.
25. Stork R, Muller D, Kontermann RE. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. Protein Eng Des Sel. 2007; 20: 569-576.
26. Vidarsson G, Stemerding AM, Stapleton NM, Spliethoff SE, Janssen H, Rebers FE, de Haas M, van de Winkel JG. FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. Blood. 2006; 108: 3573-3579.
27. 2-microglobulin gene. Proc Natl Acad Sci USA. 2006; 103: 5084-5089.
28. Xu Z, Seitz K, Fasanmade A, Ford J, Williamson PJ, Xu W, Davis HM, Zhou H. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol 2008; 48: 681-695.
29. Yang F, Bian C, Zhu L, Zhao G, Huang Z, Huang M. Effect of human serum albumin on drug metabolism: structural evidence of esterase activity of human serum albumin. J Struct Biol. 2007; 157: 348-355.